Loading
A Wuxi genomics company that co-developed TOTEM, a methylation blood test for seven cancers.
Genecast Biotechnology Co., Ltd., of Wuxi, Jiangsu, according to its authors' affiliations, co-developed TOTEM, a cell-free DNA methylation test for seven cancers with a predicted origin (BMC Cancer 2024).
Genecast's methylation blood test for seven cancers, which found about two in three cancers in a laboratory set; the developers say it still needs a large prospective study.
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/